Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality
International Journal of Neuropsychopharmacology · 17.04.2023 · 26 (4) · 259-267
DOI: 10.1093/ijnp/pyad006 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 15.02.2023. Verfasst von T E Anijärv und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thompson Institute, University of the Sunshine Coast, Birtinya, Queensland, Australia. Hauptthemen laut MEDLINE: Major Depressive Disorder, Ketamine, Suicide. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Commonwealth Government.
Abstract (Originalsprache)
Background
Ketamine has considerable therapeutic potential in alleviating major depressive disorder and chronic suicidality. However, the clinical diagnosis of neuropsychiatric disorders requires more robust diagnostic criteria. Electroencephalography (EEG) has shown promise in classifying depressive and suicidal patients from healthy individuals. The present study aimed to identify changes in the spectral properties of EEG in patients with major depressive disorder and chronic suicidality after completing the 6-week Oral Ketamine Trial on Suicidality with follow-up occurring 4 weeks after final ketamine treatment and determine associations between EEG spectral output and clinical symptoms.
Methods
Participants (n = 25) had 4-minute eyes closed resting state EEG recorded at frontal, temporal, centro-parietal, and occipital regions. Spectral analysis was performed with Welch’s power spectrum density method, and the power of 4 distinct frequency bands was analyzed: theta, alpha, low-beta, and high-beta. Correlation analyses between changes in clinical symptoms and spectral power were conducted using Spearman’s ranked correlation.
Results
Between pre- and posttreatment, only centro-parietal alpha power decreased. Between posttreatment and follow-up, centro-parietal alpha increased again in addition to increases in temporal alpha, centro-parietal and temporal theta, and occipital low-beta and decreases in occipital theta and temporal low-beta. Additionally, the decrease of occipital theta positively correlated with clinical subscales for depression and stress.
Conclusions
EEG spectral analysis revealed significant changes in theta, alpha, and low-beta frequency bands. Alpha band showed initial changes after treatment; however, this trended back toward baseline levels after the treatment cessation. In contrast, theta and low-beta showed significant power changes only after the treatment had ended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thompson Institute, University of the Sunshine Coast, Birtinya, Queensland, Australia.
ORCID-Profile: T E Anijärv
Förderung
- Australian Commonwealth Government
Zitieren
APA
Anijärv, T. E., Can, A. T., Gallay, C. C., Forsyth, G. A., Dutton, M., Mitchell, J. S., Hermens, D. F., & Lagopoulos, J. (2023). Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality. International Journal of Neuropsychopharmacology, 26(4), 259-267. https://doi.org/10.1093/ijnp/pyad006
Vancouver
Anijärv TE, Can AT, Gallay CC, Forsyth GA, Dutton M, Mitchell JS, et al. Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality. International Journal of Neuropsychopharmacology. 2023;26(4):259-267. doi:10.1093/ijnp/pyad006
BibTeX
@article{Anijrv2023,
author = {Anijärv, T E and Can, A T and Gallay, C C and Forsyth, G A and Dutton, M and Mitchell, J S and Hermens, D F and Lagopoulos, J},
title = {Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality},
journal = {International Journal of Neuropsychopharmacology},
year = {2023},
volume = {26},
number = {4},
pages = {259--267},
doi = {10.1093/ijnp/pyad006}
}
EUVIMED